Alveolar bone and the bisphosphonates.
Bisphosphonate associated osteonecrosis of the jaws (ONJ) usually commences at the alveolus. Comparison is made between the structure and function of long bones and alveolar bone and the differing susceptibilities of the bisphosphonates at these different sites are explored. Current concepts of the causation of ONJ are discussed. The clinical implications of these findings to dentists managing periodontal conditions are presented.
Cheng
A
A
Oral and Maxillofacial Surgery Unit, The University of Adelaide, South Australia, Australia.
Daly
C G
CG
Logan
R M
RM
Stein
B
B
Goss
A N
AN
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000539:Alveolar Process / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D016723:Bone Remodeling / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D008297:Male; D008336:Mandibular Diseases / Q000139:chemically induced; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced*; D010024:Osteoporosis / Q000188:drug therapy / Q000503:physiopathology; D010510:Periodontal Diseases / Q000628:therapy
D050071:Bone Density Conservation Agents; D004164:Diphosphonates